Literature DB >> 15582732

A panel of 13 region-specific radioimmunoassays for measurements of human chromogranin B.

Mats Stridsberg1, Barbro Eriksson, Kjell Oberg, Eva Tiensuu Janson.   

Abstract

INTRODUCTION: The primary structure of human chromogranin B (CgB) contains 15 pairs of basic amino acids, which are potential cleavage sites for specific endogenous proteases, but also other sites in the molecule can be subjected to cleavage. Several CgB-related peptides have been identified in tissue extracts.
MATERIALS AND METHODS: Peptides homologous to defined parts of the human CgB molecule were selected and synthesized. Antibodies were raised and 13 specific radioimmunoassays were developed. Plasma samples from 19 patients with neuroendocrine tumors were collected and measured in all assays.
RESULTS: All region-specific assays measured circulating levels of CgB-related peptides. Only five of the assays measured high concentrations of circulating CgB and two of them correlated with that of intact chromogranin A (CgA).
CONCLUSION: The assays presented allow measurements of defined regions of CgB and will thus become important tools for further studies of the processing of CgB. One of the assays merit further investigations as a new marker for neuroendocrine tumors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15582732     DOI: 10.1016/j.regpep.2004.08.027

Source DB:  PubMed          Journal:  Regul Pept        ISSN: 0167-0115


  8 in total

Review 1.  Immunohistochemical and biochemical studies with region-specific antibodies to chromogranins A and B and secretogranins II and III in neuroendocrine tumors.

Authors:  Guida M Portela-Gomes; Lars Grimelius; Mats Stridsberg
Journal:  Cell Mol Neurobiol       Date:  2010-11-03       Impact factor: 5.046

2.  Neuroendocrine inhibition of glucose production and resistance to cancer in dwarf mice.

Authors:  J McKee Alderman; Kevin Flurkey; Natasha L Brooks; Sneha B Naik; Jonathan M Gutierrez; Urmila Srinivas; Kristen B Ziara; Linhong Jing; Gunnar Boysen; Rod Bronson; Simon Klebanov; Xian Chen; James A Swenberg; Mats Stridsberg; Carol E Parker; David E Harrison; Terry P Combs
Journal:  Exp Gerontol       Date:  2008-06-07       Impact factor: 4.032

3.  Decreased cerebrospinal fluid secretogranin II concentrations in severe forms of bipolar disorder.

Authors:  Joel Jakobsson; Mats Stridsberg; Henrik Zetterberg; Kaj Blennow; Carl-Johan Ekman; Anette G M Johansson; Carl Sellgren; Mikael Landén
Journal:  J Psychiatry Neurosci       Date:  2013-07       Impact factor: 6.186

4.  Effects of chromogranin A deficiency and excess in vivo: biphasic blood pressure and catecholamine responses.

Authors:  Sucheta M Vaingankar; Ying Li; Nilima Biswas; Jiaur Gayen; Sonia Choksi; Fangwen Rao; Michael G Ziegler; Sushil K Mahata; Daniel T O'Connor
Journal:  J Hypertens       Date:  2010-04       Impact factor: 4.844

5.  Large-scale identification of endogenous secretory peptides using electron transfer dissociation mass spectrometry.

Authors:  Kazuki Sasaki; Tsukasa Osaki; Naoto Minamino
Journal:  Mol Cell Proteomics       Date:  2012-12-18       Impact factor: 5.911

6.  Immunohistochemical staining of human islet cells with region-specific antibodies against secretogranins II and III.

Authors:  M Stridsberg; L Grimelius; G M Portela-Gomes
Journal:  J Anat       Date:  2008-01-25       Impact factor: 2.610

7.  Utility of chromogranin B compared with chromogranin A as a biomarker in Japanese patients with pancreatic neuroendocrine tumors.

Authors:  Masami Miki; Tetsuhide Ito; Masayuki Hijioka; Lingaku Lee; Kohei Yasunaga; Keijiro Ueda; Takashi Fujiyama; Yuichi Tachibana; Ken Kawabe; Robert T Jensen; Yoshihiro Ogawa
Journal:  Jpn J Clin Oncol       Date:  2017-06-01       Impact factor: 3.019

8.  Secretogranin II; a protein increased in the myocardium and circulation in heart failure with cardioprotective properties.

Authors:  Helge Røsjø; Mats Stridsberg; Geir Florholmen; Kåre-Olav Stensløkken; Anett Hellebø Ottesen; Ivar Sjaastad; Cathrine Husberg; Mai Britt Dahl; Erik Øie; William E Louch; Torbjørn Omland; Geir Christensen
Journal:  PLoS One       Date:  2012-05-24       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.